In January 2015, the Centers for Disease Control and Prevention (CDC) modified its surveillance definition for CRE to the current definition:
- resistant to imipenem, meropenem, doripenem, or ertapenem OR
- documentation that the isolate possesses a carbapenemase
For details, see the CDC website, www.cdc.gov/hai/organisms/cre/definition.html.
CRE is a reportable condition in South Dakota
South Dakota CRE Workgroup
- Inter-facility transfer form
- Carbapenem-resistant Enterobacteriaceae (CRE) Screening Recommendations for South Dakota healthcare facilities
- Interim Duodenscope Surveillance Protocol (CDC)
Additional Resources
- Epidemiological Profile of Carbapenem-resistant Enterobacteriaceae (CRE) - South Dakota, 2013-2016
- Patients: Information about CRE (CDC)
- Clinicians: Information about CRE (CDC)
- 2015 CRE Toolkit - Guidance for Control of Carbapenem-resistant Enterobacteriaceae (CDC)
- HAI Outbreaks in Healthcare Settings (CDC)
- Carbapenem-resistant Enterobacteriaceae (CRE) Infection: Patient FAQs (CDC)
- Carbapenem-resistant Enterobacteriaceae Control and Prevention Toolkit - Agency for Healthcare Research and Quality